论文部分内容阅读
2012年11月,美国FDA批准利伐沙班片剂(rivaroxaban/Xarelto)治疗深静脉血栓(DVT)或肺栓塞(PE)形成以及减少DVT和PE初始治疗后的复发风险。利伐沙班先前已经获得FDA批准用于膝或髋关节置换手术后减少DVT和PE的发生风险以及减少非瓣膜性心房纤维性颤动患者的卒中风险。已获FDA批准治疗或减少血液凝块风险的其它药物有依诺肝素注射剂
In November 2012, the US FDA approved rivaroxaban / Xarelto tablets for the treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE) and to reduce the risk of recurrence after initial treatment with DVT and PE. Rivaroxaban has previously received FDA approval for reducing the risk of DVT and PE after knee or hip replacement surgery and for reducing the risk of stroke in patients with nonvalvular atrial fibrillation. Other drugs approved by the FDA for treatment or reduction of blood clotting include enoxaparin